Business, energy, technology, markets and global industry news from Business News Today

HBM9378

PharmaDeviceNews HBM9378
Harbour BioMed’s antibody discovery platforms and global biopharma partnerships are supporting revenue growth and a seventh consecutive profitable half-year, although the company’s full interim results will determine the durability of its earnings momentum. Representative image.
Pharma & Biotech

Harbour BioMed’s revenue is climbing, but one profit number complicates the growth story

Harbour BioMed expects up to $67 million interim profit as antibody deals lift revenue, but margin trends will shape the next investor debate.

Read More
Pharma & Biotech

Harbour BioMed HBM9378 Phase I data: does long-acting TSLP inhibition change asthma treatment economics?

Harbour BioMed’s HBM9378 Phase I data shows long half-life and safety. Find out what this means for asthma, COPD, and TSLP competition.

Read More